PFE changes
Pick any two versions below to diff them.
- Price
- $30.00 → $29.45(−1.8%)
- Recent events
- Nov 3, 2026: added: Pfizer's board named Cecile Guegan Chief Financial Officer and Executive Vice President, from November 1, 2026. She had been Interim CFO since August 16, 2026, and has worked in Pfizer added: finance roles since 2009. Nov 3, 2026: Pfizer reported Q3 2026 results. Revenue was $16.6 billion, flat at constant exchange rates, and revenue without Comirnaty and Paxlovid grew 7%. Launched and acquired products grew 32%. Reported EPS was $0.56 and adjusted EPS was $0.87, the same as a year earlier, after a $650 million charge for the Innovent license. Pfizer raised its 2026 guidance to revenue of $62.0 billion to $64.0 billion and adjusted EPS of $2.95 to $3.05. It also named Cecile Guegan as CFO from November 1, 2026. The release lists October 2026 news: the FDA approved Talzenna with Xtandi for men with metastatic prostate cancer with HRR gene mutations and Tukysa as a first-line maintenance treatment in HER2-positive breast cancer, and the Phase 3 MagnetisMM-32 study of Elrexfio in multiple myeloma met its main goal. Oct 6, 2026: Pfizer declared a fourth-quarter 2026 dividend of $0.43 per share, payable on December 7, 2026. Sep 22, 2026: Pfizer said that it will report Q3 2026 results on November 3, 2026. Aug 4, 2026: Pfizer reported Q2 2026 results. Revenue was $15.0 billion, up 3% (1% at constant exchange rates). It had a reported loss of $0.04 per share because of $4.3 billion of impairments, and adjusted EPS was $0.77. Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion and kept its adjusted EPS guidance of $2.80 to $3.00. It also announced $2.5 billion of additional cost savings, expected from 2027 through 2029. Jul 10, 2026: Pfizer completed its licensing agreement with Innovent Biologics for 12 early-stage cancer medicines. Innovent received $650 million upfront and can receive up to $9.85 billion more in milestone payments. Pfizer records the upfront payment as a charge in Q3 2026, which lowers 2026 adjusted EPS by about $0.10. Jun 18, 2026: Pfizer said that CFO Dave Denton will leave on August 15, 2026. Cecile Guegan became Interim CFO on August 16 while Pfizer searches for a new CFO. In June 2026, Pfizer also presented Phase 2b results for berobenatide, a monthly obesity medicine, and its Phase 3 lung cancer study of sigvotatug vedotin did not meet its main goal.